doi:10.3969/j.issn.1004-3594.2026.09.010

PDF(2187 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2026, Vol. 37 ›› Issue (9) : 785-787. DOI: 10.3969/j.issn.1004-3594.2026.09.010

CLINICAL EXPERIENCE

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

References

[1] Moch H, Cubilla A L, Humphrey P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105.
[2] 冯润林, 王小芳, 华结, 等. 肾脏黏液样小管状和梭形细胞癌4例临床病理分析[J]. 临床泌尿外科杂志,2021,36(10):823-826.
[3] 李平, 唐朝朋, 吴鼎, 等. 肾黏液样小管状和梭形细胞癌一例[J]. 临床外科杂志,2024,32(5):510-511.
[4] 沈棋, 刘亿骁, 何群. 肾黏液样小管状和梭形细胞癌的临床病理特点及预后[J]. 北京大学学报(医学版),2023,55(2):276-282.
[5] 王劭亮, 王书龙, 陈蓉, 等. 肾单位保留术治疗解剖性孤立肾肾癌的临床疗效[J]. 武警医学,2025,36(2):93-96.
[6] Tsang S L, Hsu S S, An C, et al. Mucinous tubular and spindle cell carcinoma: case report and literature review[J]. J Kidney Cancer VHL, 2025, 12(1): 6-11.
[7] Wang H, Peng X, Li L, et al. A retrospective study of imaging characteristics of mucinous tubular and spindle cell carcinoma in the kidney[J]. Front Oncol, 2025, 15: 1515569.
[8] Kang H, Xu W, Chang S, et al. Mucinous tubular and spindle cell carcinomas of the kidney (MTSCC-Ks): CT and MR imaging characteristics[J]. Jpn J Radiol, 2022, 40(11): 1175-1185.
[9] Takahashi H, Vikram R, Jimenez R E, et al. MR characteristics of mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: comparison with clear cell and papillary subtypes of renal cell carcinoma[J]. Abdom Radiol (NY), 2021, 46(11): 5250-5259.
[10] Ling C, Tan R, Li J, et al. Mucinous tubular and spindle cell carcinoma of the kidney: a report of seven cases[J]. BMC Cancer, 2023, 23(1): 815.
[11] Xu X, Zhong J, Zhou X, et al. Mucinous tubular and spindle cell carcinoma of the kidney: a study of clinical, imaging features and treatment outcomes[J]. Front Oncol, 2022, 12: 865263.
[12] Bhardwaj N, Parkhi M, Chatterjee D, et al. Mucinous tubular and spindle cell carcinoma of the kidney[J]. Autops Case Rep, 2023, 13: e2023415.
[13] Sadimin E T, Chen Y B, Wang L, et al. Chromosomal abnormalities of high-grade mucinous tubular and spindle cell carcinoma of the kidney[J]. Histopathology, 2017, 71(5): 719-724.
[14] Tamir K T, Ademe S A, Mikru A M, et al. Mucinous tubular and spindle cell carcinoma very rare variant kidney cancer: case report[J]. Int J Surg Case Rep, 2024, 123: 110193.
[15] Fuchizawa H, Kijima T, Takada-Owada A, et al. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab[J]. IJU Case Rep, 2021, 4(5): 333-337.
[16] Makker S, Shah N J, Carlo M I, et al. Immune checkpoint blockade response in mucinous tubular and spindle cell carcinoma[J]. Curr Oncol, 2025, 32(2): 94.
[17] Furubayashi N, Taguchi K, Negishi T, et al. Cytoreductive nephrectomy after combination of nivolumab plus ipilimumab for mucinous tubular and spindle cell carcinoma of the kidney with bone metastases: a case report[J]. In Vivo, 2022, 36(1): 510-521.
[18] Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma[J]. N Engl J Med, 2018, 379(5): 417-427.
[19] Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial[J]. JAMA Oncol, 2019, 5(2): 164-170.